Mineralys Therapeutics (MLYS) Stock: Buy, Sell, or Hold?
MLYS - Mineralys Therapeutics, Inc. Common Stock
$28.20
-1.10 (-3.75%)
âŧ
5d:
-0.25%
30d:
+4.25%
90d:
+17.79%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When MLYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MLYS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MLYS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: MLYS is currently trading at $28.20, which is considered slightly high relative to its 30-day fair value range of $25.51 to $28.48.
Technical Outlook: Technically, MLYS is showing sideways momentum. Immediate support is located at $24.98, while resistance sits at $31.99. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: MLYS scores 3/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $48.50 (+72.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MLYS is showing sideways momentum. Immediate support is located at $24.98, while resistance sits at $31.99. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: MLYS scores 3/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $48.50 (+72.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$25.51 -
$28.48
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
36.8%
Protect Your Profits
Holding MLYS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (3/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 72.0% below Wall St target ($48.50)
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$25.51 -
$28.48
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$24.98
Resistance Level
$31.99
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.28
Wall Street Target
$48.50
(+72.0%)
Share & Embed Analysis
Last updated: September 12, 2026 5:44 AM ET
Data refreshes hourly during market hours. Next update: 6:44 AM
Data refreshes hourly during market hours. Next update: 6:44 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MLYS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
David Malcom Rodman
SELL
416 shares
2026-04-17
David Malcom Rodman
SELL
6348 shares
2026-04-15
David Malcom Rodman
SELL
14058 shares
2026-04-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
Advanced MLYS Option Strategies
Professional options setups generated by AI based on today's MLYS price and gamma walls.
